Wall St ends lower as taper acceleration worries pile onto virus angst



(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)

By Devik Jain, Ambar Warrick and Sinéad Carew

Nov 30 (Reuters) - Wall Street's main indexes closed lower on Tuesday after Federal Reserve Chair Jerome Powell signaled that the U.S. central bank would consider speeding up its withdrawal of bond purchases as inflation risks increase, piling pressure onto a market already nervous about the latest COVID-19 variant.

In a testimony before the Senate Banking Committee, Powell indicated that he no longer considers high inflation as "transitory" and that the Fed would revisit the timeline for scaling back its bond buying program at its next meeting in two weeks.

"Powell's comments threw a monkey in the wrench in market thinking in terms of potential taper timing. You're seeing as a result of that, risk-off across the board," said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.

"You also have to factor in the Omicron variant concerns. You can argue whether they're more headline risk or reality risk but regardless, it's having a significant impact on oil, and everything that's tied to economic growth."

Powell's comments also prompted speculation among some investors about a potential acceleration in interest rate hikes.

"The principal contributor to the decline in stock prices today is the Powell commentary, regarding the upcoming Fed meeting, about accelerating the tapering of their bond buying program, which obviously leads to the prospect that rate hikes come sooner next year," said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.

"That somewhat hawkish shift in tone caught the market flatfooted," Luschini said.

Meanwhile, the market was also left waiting for information about how dangerous the Omicron variant might be, the degree to which current vaccinations could offer protection and the additional restrictions governments might have to impose that could hurt the economy, Luschini said.

According to preliminary data, the S&P 500 .SPX lost 87.25 points, or 1.87%, to end at 4,568.02 points, while the Nasdaq Composite .IXIC lost 239.43 points, or 1.52%, to 15,543.40. The Dow Jones Industrial Average .DJI fell 648.13 points, or 1.84%, to 34,487.81.

The declines were broad-based, with all the 11 major S&P sectors down. Communication services .SPLRCL was the lead decliner by late afternoon. As oil prices tumbled energy .SPNY were also under pressure throughout the session.

Tuesday's decline was a reversal after Monday's rally in which stocks regained some of the ground they had lost on Friday when the market first sold-off on news of the virus variant.

"The market is clearly in some treacherous waters right now. You've had two significant pullbacks out of the last three trading days. This is certainly shaking some of the complacent longs in the market," said Wedbush's James.

While the Food and Drug Administration said it hopes to have information about the effectiveness of current COVID-19 vaccines against Omicron, vaccine companies appeared divided.

BioNTech's 22UAy.DE chief executive said the BioNTech and Pfizer PFE.N COVID-19 vaccine will likely offer strong protection against severe disease from the variant, while Moderna Inc's MRNA.O CEO told the Financial Times that COVID-19 shots are unlikely to be as effective against the new variant as they have been previously.

Moderna shares fell while Regeneron Pharmaceuticals Inc REGN.O were also under pressure after it said its COVID-19 antibody treatment and other similar drugs could be less effective against Omicron.

Travel and leisure stocks slumped, with S&P 1500 Airlines .SPCOMAIR and the S&P 1500 Hotels, Restaurant and Leisure .SPCOMHRL indexes both declining on concerns of more border restrictions.

The small-cap Russell 2000 index .RUT also fell.

The virus uncertainty has triggered fresh alarm at a time when supply chain logjams are weighing on economic recovery and central banks globally are contemplating a return to pre-pandemic monetary policy to tackle a surge in inflation.

Meanwhile, data showed U.S. consumer confidence slipped in November amid concerns about the rising cost of living and relentless COVID-19 pandemic.
Reporting by Devik Jain and Ambar Warrick in Bengaluru; Editing by Marguerita Choy and Sriraj Kalluvila

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.